RASA2 (Ras GTPase-Activating Protein 2): A Comprehensive Review

Introduction

RASA2 (RAS p21 protein activator 2), also known as GAP1m (GTPase-activating protein 1m), is a member of the GAP1 family of RasGAPs that functions as a negative regulator of RAS signaling. The protein stimulates the intrinsic GTPase activity of RAS proteins, converting them from the active GTP-bound state to the inactive GDP-bound form, thereby serving as a critical brake on RAS-mediated mitogenic signaling [maekawa-1994-gap1m-abstract]. Located on human chromosome 3q23, RASA2 encodes an 853-amino acid protein with a characteristic modular architecture comprising two N-terminal C2 domains, a central RasGAP catalytic domain, and a C-terminal pleckstrin homology (PH) domain with a Bruton's tyrosine kinase (BTK) motif [li-1996-human-gap1m-abstract]. RASA2 was identified based on its strong sequence similarity to Drosophila Gap1, a known suppressor of RAS function in fruit flies, establishing it as the mammalian counterpart of this evolutionarily conserved signaling regulator [maekawa-1994-gap1m-abstract].

Recent research has revealed RASA2 as a critical signaling checkpoint in T cell biology and a tumor suppressor in melanoma, highlighting its importance in both normal immune function and cancer development [carnevale-2022-tcells-abstract][arafeh-2015-melanoma-abstract]. Loss-of-function mutations in RASA2 have been associated with developmental syndromes including Noonan syndrome, underscoring the protein's essential role in proper RAS pathway regulation during development [chen-2014-noonan-abstract].

Molecular Function and Catalytic Mechanism

RASA2 functions as a GTPase-activating protein that accelerates the hydrolysis of GTP bound to RAS proteins. RAS proteins possess weak intrinsic GTPase activity (approximately 4.7 × 10⁻⁴ s⁻¹ at 37°C), but RasGAPs like RASA2 can enhance this rate approximately 100,000-fold [sondermann-2019-rasgap-review-abstract]. This dramatic acceleration is achieved through a transition state stabilization mechanism that depends on the conserved "arginine finger" motif present in the GAP catalytic domain.

The catalytic mechanism involves the insertion of a critical arginine residue into the nucleotide-binding pocket of RAS. This arginine finger (corresponding to Arg789 in p120GAP/RASA1) performs dual functions: it stabilizes the position of the catalytic glutamine residue (Gln61) of RAS and neutralizes developing negative charges on the phosphate groups during the hydrolysis reaction [sondermann-2019-rasgap-review-abstract]. The carbonyl oxygen on the arginine finger backbone interacts with a water molecule that forms a bridge between the NH₂ group of Gln61 and the γ-phosphate of GTP, helping to generate and position the nucleophilic water molecule for attack on the phosphate bond. Importantly, RASA2 stimulates the GTPase activity of wild-type RAS but not oncogenic RAS variants harboring mutations at key catalytic residues such as valine substitution at position 12 [maekawa-1994-gap1m-abstract].

Recombinant protein studies have confirmed that the isolated GAP-related domain of RASA2 is sufficient for catalytic activity. Expression of this domain in Saccharomyces cerevisiae suppressed the ira2⁻ phenotype, providing functional evidence that RASA2 acts as a bona fide RAS-specific GAP [maekawa-1994-gap1m-abstract]. However, surrounding domains, particularly the C2 domains, appear to augment full catalytic activity, consistent with findings from related dual-specificity GAPs [sondermann-2019-rasgap-review-abstract].

Substrate Specificity

Among the GAP1 family members, RASA2 shows preferential activity toward RAS over RAP1, distinguishing it from closely related family members such as RASA3 (GAP1IP4BP), RASA4 (CAPRI), and RASAL1, which demonstrate dual RAS/RAP1 specificity [johansen-2023-mindthegap-abstract]. Studies in T cells have shown that CRISPR-Cas9-mediated targeting of RASA2 leads to increased GTP-bound RAS levels and enhanced phosphorylation of downstream effectors ERK and S6, confirming its role as a RAS-specific GAP in physiological contexts [johansen-2023-mindthegap-abstract].

Particularly noteworthy is the apparent isoform selectivity of RASA2 for NRAS over other RAS family members. Work by Arafeh and colleagues demonstrated that RNAi-mediated suppression of RASA2 in melanoma cells led to activation of NRAS-GTP, but not HRAS or KRAS [arafeh-2019-nf1-rasa2-abstract]. Conversely, overexpression of wild-type RASA2 substantially suppressed NRAS-GTP levels. This finding has significant implications for understanding melanoma biology, where NRAS is frequently mutated, and suggests that RASA2 and NF1 (which preferentially targets KRAS and HRAS) may have complementary functions in regulating different RAS isoforms [arafeh-2019-nf1-rasa2-abstract].

Domain Architecture and Regulatory Features

C2 Domains

RASA2 contains two tandem C2 domains (C2A and C2B) at its N-terminus. C2 domains are approximately 130-residue modules arranged as eight β antiparallel strands forming a β sandwich structure. While C2 domains are classically associated with calcium-dependent phospholipid binding, not all C2 domains exhibit these properties. The C2 domains of RasGAPs, including RASA2, are positioned immediately N-terminal to the GAP domain—a configuration conserved in nine of ten RAS-specific GAPs (with neurofibromin being the exception) [sondermann-2019-rasgap-review-abstract].

The C2 domains appear to contribute to full catalytic activity. Studies on related GAPs such as SynGAP have shown that the presence of the C2 domain augments catalytic activity against both RAS and the related GTPase RAP. Similarly, in dual-specificity RasGAPs including RASA2, RASA3, and RASAL1, the C2 domain confers a catalytic advantage compared to the GAP domain alone [sondermann-2019-rasgap-review-abstract]. The precise mechanism of this enhancement remains under investigation, but may involve intramolecular interactions that optimize GAP domain positioning or interactions with partner proteins.

Pleckstrin Homology Domain and BTK Motif

The C-terminal region of RASA2 contains a pleckstrin homology (PH) domain connected to a Bruton's tyrosine kinase (BTK) motif. The PH domain of RASA2 binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3), enabling membrane recruitment in response to PI3K activation [johansen-2023-mindthegap-abstract][shen-2017-nonredundant-rasgaps-abstract]. This PIP3-dependent recruitment creates a negative feedback loop: activation of PI3K (which can be promoted by RAS) generates PIP3, which recruits RASA2 to the membrane where it can inactivate RAS.

Importantly, the PH domain of RASA2 also binds inositol 1,3,4,5-tetrakisphosphate (IP4) with high affinity and specificity [fukuda-1996-ip4-binding-abstract]. Structure-function studies have demonstrated that while the PH domain is the central IP4-binding domain, optimal binding requires an adjacent GAP-related domain and carboxyl terminus. A mutation replacing arginine with cysteine at position 628 in the PH domain (corresponding to the mutation in Bruton's tyrosine kinase observed in X-linked immunodeficiency mice) dramatically reduces both IP4 and phospholipid binding capacity [fukuda-1996-ip4-binding-abstract]. These findings indicate that the PH domain functions as a modulatory domain of GAP activity through its ability to bind both IP4 and phospholipids.

This regulatory mechanism distinguishes RASA2 from RASA3, whose PH domain additionally recognizes phosphatidylinositol (4,5)-bisphosphate (PIP2), allowing for constitutive membrane association. The consequence is that RASA2 is recruited to membranes upon PI3K activation, while RASA3 is found constitutively at membranes [johansen-2023-mindthegap-abstract]. The BTK motif, related to sequences found in Bruton's tyrosine kinase, participates in additional regulatory interactions including IP4 binding.

Subcellular Localization

RASA2 is primarily localized to the cytoplasm and cytosol, with characteristic enrichment in the perinuclear region [shen-2017-nonredundant-rasgaps-abstract][lockyer-1997-localization-abstract]. This perinuclear localization distinguishes RASA2 from its close relative RASA3 (GAP1IP4BP), which localizes constitutively to the plasma membrane. Expression studies in COS-7 and HeLa cells demonstrated that while RASA3 is located solely at the plasma membrane, RASA2 maintains a distinct perinuclear distribution [lockyer-1997-localization-abstract]. Mutational analysis has established that this difference in subcellular distribution is determined by the respective PH domains of these proteins, highlighting the functional specialization within the GAP1 family.

Upon PI3K activation and PIP3 generation at the plasma membrane, RASA2 can translocate to the membrane where it encounters its RAS substrates. This dynamic localization allows RASA2 to function as a signal-responsive brake on RAS activity, being recruited specifically when and where PI3K signaling is active. The membrane targeting capacity of RASA2 is critical for its biological function, bringing it into proximity with membrane-associated RAS proteins that cycle between the plasma membrane and endomembranes. The requirement for PI3K-dependent membrane recruitment suggests that RASA2 primarily functions during active signaling states rather than providing constitutive suppression of RAS activity, in contrast to the constitutively membrane-localized RASA3.

Role in RAS-MAPK Signaling Pathway

RASA2 functions as a negative regulator within the RAS-RAF-MEK-ERK (MAPK) signaling cascade, one of the most fundamental pathways controlling cell proliferation, differentiation, and survival. In this pathway, growth factors binding to receptor tyrosine kinases (RTKs) such as EGFR or PDGFR trigger receptor autophosphorylation and recruitment of adaptor proteins including GRB2. GRB2 in turn recruits guanine nucleotide exchange factors (GEFs) such as SOS1/2 and RASGRP1 that activate RAS by promoting GDP-to-GTP exchange. Active GTP-bound RAS then initiates the RAF-MEK-ERK kinase cascade, ultimately leading to activation of transcription factors and changes in gene expression [johansen-2023-mindthegap-abstract].

RASA2 counteracts this activation by accelerating GTP hydrolysis on RAS, returning it to the inactive GDP-bound state. Studies in T cells have demonstrated that RASA2 ablation enhances MAPK signaling, as evidenced by increased phosphorylation of ERK and downstream targets like S6 [carnevale-2022-tcells-abstract]. RASA2-deficient T cells show increased activation, cytokine production, and metabolic activity compared to control cells, reflecting the enhanced RAS-MAPK signaling in these cells [carnevale-2022-tcells-abstract].

An important aspect of RASA2 regulation is its expression-level control during signaling. Both RASA2 and RASA3 are markedly repressed upon T cell receptor (TCR) stimulation in both mouse and human T cells [johansen-2023-mindthegap-abstract]. This downregulation releases the brake on RAS (and RAP1) signaling, allowing full T cell activation. In contrast, RASA2 levels increase gradually with chronic antigen exposure, potentially contributing to T cell exhaustion in contexts of persistent stimulation [carnevale-2022-tcells-abstract].

Role in T Cell Biology

Recent genome-wide CRISPR knockout screens have identified RASA2 as a critical signaling checkpoint in human T cells [carnevale-2022-tcells-abstract]. These screens, performed under immunosuppressive conditions designed to identify genes whose loss prevents T cell dysfunction, converged on RASA2 as a key regulatory target. The findings have significant implications for cancer immunotherapy, as RASA2 ablation can enhance both the sensitivity and persistence of anti-tumor T cell responses.

RASA2 ablation in T cells results in enhanced MAPK signaling and increased cytolytic activity in response to target antigens. Repeated tumor antigen stimulations in vitro revealed that RASA2-deficient T cells maintain increased activation, cytokine production, and metabolic activity compared with control cells [carnevale-2022-tcells-abstract]. Importantly, RASA2-deficient T cells show a marked advantage in persistent cancer cell killing, suggesting that RASA2 normally limits the long-term anti-tumor efficacy of T cells.

In preclinical models, RASA2-knockout chimeric antigen receptor (CAR) T cells demonstrated a competitive fitness advantage over control cells in the bone marrow in mouse models of leukemia. Ablation of RASA2 in multiple preclinical models of both T cell receptor (TCR) and CAR T cell therapies prolonged survival in mice bearing liquid or solid tumors [carnevale-2022-tcells-abstract]. These findings highlight RASA2 as a promising genetic target for enhancing both persistence and effector function in T cell therapies for cancer treatment.

The mechanism by which RASA2 limits T cell function appears to be activation-dependent. In the absence of TCR stimulation, RASA2 ablation does not result in unregulated MAPK signaling or altered T cell activation, proliferation, or viability [johansen-2023-mindthegap-abstract]. This suggests that RASA2 functions as a context-specific brake that engages primarily during active signaling states, consistent with its PI3K-dependent membrane recruitment.

Role as a Tumor Suppressor

Analysis of 501 melanoma exomes identified RASA2 as a tumor suppressor gene mutated in approximately 5% of melanomas [arafeh-2015-melanoma-abstract]. The mutations include both nonsense mutations (such as p.Arg310*) and missense mutations affecting the RAS-GAP domain (such as p.Ser400Phe). Functional characterization demonstrated that these mutations represent loss-of-function alleles: while wild-type RASA2 substantially suppressed RAS-GTP levels in reconstitution experiments, mutant RASA2 proteins failed to suppress RAS-GTP [arafeh-2015-melanoma-abstract].

The biological consequences of RASA2 loss are consistent with its tumor suppressor function. RASA2 knockdown in NIH3T3 cells resulted in RAS activation leading to increased cell growth on plastic and in soft agar. Cells expressing mutant RASA2 showed significantly higher colony formation in soft agar compared to wild-type RASA2 and failed to suppress migration [arafeh-2015-melanoma-abstract].

Clinical analysis revealed that RASA2 expression was lost in at least 30% of human melanomas examined by immunohistochemistry. Loss of RASA2 expression was significantly associated with poorer patient survival (HR=0.42, log rank p=0.0043), underscoring its clinical relevance as a prognostic marker [arafeh-2015-melanoma-abstract].

The relationship between RASA2 and NF1 in melanoma is particularly informative. Both proteins function as RasGAPs, but they show distinct substrate preferences: RASA2 preferentially targets NRAS, while NF1 targets KRAS and HRAS [arafeh-2019-nf1-rasa2-abstract]. Mutations in RASA2 and NF1 co-occur significantly in melanoma (p=0.000011, Fisher's Exact Test), particularly in BRAF and NRAS wild-type tumors. Conversely, RASA2 and NRAS mutations are mutually exclusive, consistent with RASA2's role in suppressing NRAS activity. These observations suggest that combined loss of RASA2 and NF1 may be functionally equivalent to oncogenic RAS mutation, as it would result in constitutive activation of all RAS isoforms [arafeh-2019-nf1-rasa2-abstract].

Disease Associations

Noonan Syndrome

Loss-of-function mutations in RASA2 have been identified in patients with Noonan syndrome (NS), a developmental disorder characterized by distinctive facial features, short stature, congenital heart defects, and variable developmental delay [chen-2014-noonan-abstract]. Noonan syndrome and related disorders (collectively termed "RASopathies") are caused by germline mutations that increase RAS-MAPK pathway signaling.

Next-generation sequencing of 27 NS patients lacking mutations in previously known causative genes identified three patients with missense mutations in RASA2 affecting two residues: Y326C, Y326N (affecting the same codon), and R511C [chen-2014-noonan-abstract]. All mutations affect highly conserved amino acids within the GAP domain. Structural modeling based on the p120GAP structure predicts that R511 is a direct contact site for RAS, and MAPP analysis indicates that all three NS-associated mutations damage RASA2 function.

Expression of mutant RASA2 alleles in heterologous cells increased RAS-ERK pathway activation, supporting a causative role in NS pathogenesis [chen-2014-noonan-abstract]. All patients were heterozygous for their RASA2 allele, suggesting haploinsufficiency as the disease mechanism—a previously unreported mechanism of NS pathogenesis that is distinct from the gain-of-function mutations in RAS pathway components typically associated with RASopathies. However, the R511C variant appears to have dominant negative effects [chen-2014-noonan-abstract].

Melanoma

As detailed above, RASA2 functions as a tumor suppressor in melanoma, with loss-of-function mutations or expression loss occurring in a substantial fraction of cases and correlating with worse patient outcomes [arafeh-2015-melanoma-abstract].

Other Cancers

Examination of publicly available databases has revealed that RASA2 is mutated in several tumor types beyond melanoma. RASA2 loss-of-function mutations have been implicated in multiple myeloma, as well as cervical and head and neck cancers, where early-termination mutations similar to those found in melanoma have been identified [arafeh-2015-melanoma-abstract]. In relapsed refractory multiple myeloma (RRMM), RASA2 truncating mutations have been identified as part of the genetic alterations affecting the RAS/MAPK pathway, which is altered in 45-65% of these cases. However, RASA2 is typically co-mutated with other tumor suppressors such as NF1, suggesting reduced transformation potential as a single mutation and implying that RASA2 loss cooperates with other genetic hits to drive tumorigenesis.

Tissue Expression and Distribution

RASA2 shows relatively broad tissue distribution, consistent with its classification among the ubiquitously distributed RasGAPs alongside RASA1, NF1, DAB2ip, and RASAL2 [shen-2017-nonredundant-rasgaps-abstract]. Original characterization of the rat homolog (Gap1m) revealed relatively high expression in brain, placenta, and kidney, with lower expression in other tissues [maekawa-1994-gap1m-abstract]. The human ortholog shows a similar pattern.

In the immune system, RASA2 is expressed in both CD4+ and CD8+ T cells [johansen-2023-mindthegap-abstract]. Expression is dynamically regulated: RASA2 is rapidly downregulated upon TCR stimulation but can increase gradually with chronic antigen exposure, as observed in exhausted T cells during chronic infection. Gene expression databases indicate highest RPKM values in lymph node and appendix, consistent with significant expression in lymphoid tissues.

Evolutionary Conservation

RASA2 belongs to the GAP1 family of RasGAPs, which was identified based on homology to Drosophila Gap1. The amino acid sequence of RASA2 shows high similarity to the entire sequence of Drosophila Gap1, with the highest similarity observed in the catalytic domain when compared to Gap1, p120GAP, and neurofibromin [maekawa-1994-gap1m-abstract]. The human RASA2 protein (853 amino acids) is 89.4% identical to its rat ortholog, indicating strong conservation across mammals [li-1996-human-gap1m-abstract].

In Drosophila, Gap1 terminates RAS1 signaling downstream of receptor tyrosine kinases and the GEF Son-of-sevenless (Sos), playing critical roles in eye development and adult appendage patterning. Flies bearing mutations in both Gap1 and NF1 appear to be inviable, suggesting partial functional redundancy between these GAPs [shen-2017-nonredundant-rasgaps-abstract]. This evolutionary conservation underscores the fundamental importance of GAP1 family proteins in RAS pathway regulation.

Open Questions

Despite significant advances in understanding RASA2 function, several important questions remain unresolved:

1. Detailed biochemical characterization: Comprehensive kinetic analysis of RASA2's catalytic activity toward different RAS isoforms and under varying conditions has not been reported. Understanding the quantitative parameters of RASA2 catalysis would help explain its apparent selectivity for NRAS.

2. Structural basis of isoform selectivity: The molecular basis for RASA2's preferential activity toward NRAS over HRAS and KRAS remains unclear. Crystal structures of RASA2 in complex with different RAS isoforms would be valuable.

3. Regulation by post-translational modifications: Whether RASA2 activity is regulated by phosphorylation or other post-translational modifications is not well characterized. Understanding such regulation could reveal additional layers of control.

4. Functions beyond catalytic activity: Whether RASA2 has scaffolding or other non-catalytic functions, as reported for some other RasGAPs, has not been explored in detail.

5. Tissue-specific physiological roles: Despite broad expression, the specific tissues and contexts where RASA2 is physiologically essential remain unclear. Conditional knockout studies would help address this question.

6. Therapeutic targeting: While RASA2 ablation enhances T cell anti-tumor activity, the potential consequences of systemic RASA2 inhibition (e.g., in non-immune cells) require careful consideration for therapeutic applications.

7. Relationship with other RasGAPs: How RASA2 cooperates or competes with other RasGAPs in physiological contexts is incompletely understood.

References

• [maekawa-1994-gap1m-abstract]: Maekawa M, Li S, Iwamatsu A, Morishita T, Yokota K, Imai Y, Kohsaka S, Nakamura S, Hattori S. A novel mammalian Ras GTPase-activating protein which has phospholipid-binding and Btk homology regions. Mol Cell Biol. 1994 Oct;14(10):6879-85. PMID: 7935405. PMCID: PMC359218. DOI: 10.1128/mcb.14.10.6879-6885.1994. https://pubmed.ncbi.nlm.nih.gov/7935405/

• [li-1996-human-gap1m-abstract]: Li S, Satoh H, Watanabe T, Nakamura S, Hattori S. cDNA cloning and chromosomal mapping of a novel human GAP (GAP1M), a GTPase-activating protein of Ras. Genomics. 1996 Aug 1;35(3):625-7. PMID: 8812506. DOI: 10.1006/geno.1996.0412. https://pubmed.ncbi.nlm.nih.gov/8812506/

• [arafeh-2015-melanoma-abstract]: Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015 Dec;47(12):1408-10. PMID: 26502337. PMCID: PMC4954601. DOI: 10.1038/ng.3427. https://pubmed.ncbi.nlm.nih.gov/26502337/

• [carnevale-2022-tcells-abstract]: Carnevale J, Shifrut E, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 Sep;609(7925):174-182. PMID: 36002574. PMCID: PMC9433322. DOI: 10.1038/s41586-022-05126-w. https://pubmed.ncbi.nlm.nih.gov/36002574/

• [johansen-2023-mindthegap-abstract]: Johansen KH, Golec DP, Okkenhaug K, Schwartzberg PL. Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion. Trends Immunol. 2023 Nov;44(11):917-931. PMID: 37858490. DOI: 10.1016/j.it.2023.09.002. https://pubmed.ncbi.nlm.nih.gov/37858490/

• [chen-2014-noonan-abstract]: Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11473-8. PMID: 25049390. PMCID: PMC4128129. DOI: 10.1073/pnas.1324128111. https://pubmed.ncbi.nlm.nih.gov/25049390/

• [sondermann-2019-rasgap-review-abstract]: Sondermann H, Grundke C, Smerdon SJ. Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions. Cold Spring Harb Perspect Med. 2019 Mar;9(3):a031500. PMCID: PMC6396337. DOI: 10.1101/cshperspect.a031500. https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/

• [arafeh-2019-nf1-rasa2-abstract]: Arafeh R, Di Pizio A, Elkahloun AG, Dym O, Niv MY, Samuels Y. RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma. Oncogene. 2019 Mar;38(13):2432-2434. PMID: 30478445. DOI: 10.1038/s41388-018-0578-4. https://pubmed.ncbi.nlm.nih.gov/30478445/

• [shen-2017-nonredundant-rasgaps-abstract]: Shen MH, et al. Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis. Sci Signal. 2017 Jun. PMCID: PMC5483993. https://pmc.ncbi.nlm.nih.gov/articles/PMC5483993/

• [fukuda-1996-ip4-binding-abstract]: Fukuda M, Mikoshiba K. Structure-function relationships of the mouse Gap1m. Determination of the inositol 1,3,4,5-tetrakisphosphate-binding domain. J Biol Chem. 1996 Aug 2;271(31):18838-42. PMID: 8702543. DOI: 10.1074/jbc.271.31.18838. https://pubmed.ncbi.nlm.nih.gov/8702543/

• [lockyer-1997-localization-abstract]: Lockyer PJ, Bottomley JR, Reynolds JS, McNulty TJ, Venkateswarlu K, Potter BV, Dempsey CE, Cullen PJ. Distinct subcellular localisations of the putative inositol 1,3,4,5-tetrakisphosphate receptors GAP1IP4BP and GAP1m result from the GAP1IP4BP PH domain directing plasma membrane targeting. Curr Biol. 1997 Dec 1;7(12):1007-10. PMID: 9382842. DOI: 10.1016/s0960-9822(06)00423-4. https://pubmed.ncbi.nlm.nih.gov/9382842/

• OMIM Entry 601589: RAS p21 PROTEIN ACTIVATOR 2; RASA2. https://omim.org/entry/601589

• NCBI Gene ID 5922: RASA2 RAS p21 protein activator 2 [Homo sapiens (human)]. https://www.ncbi.nlm.nih.gov/gene/5922

Citations

1. arafeh-2015-melanoma-abstract.md
2. arafeh-2015-melanoma-summary.md
3. arafeh-2019-nf1-rasa2-abstract.md
4. carnevale-2022-tcells-abstract.md
5. carnevale-2022-tcells-summary.md
6. chen-2014-noonan-abstract.md
7. fukuda-1996-ip4-binding-abstract.md
8. johansen-2023-mindthegap-abstract.md
9. li-1996-human-gap1m-abstract.md
10. lockyer-1997-localization-abstract.md
11. maekawa-1994-gap1m-abstract.md
12. maekawa-1994-gap1m-summary.md
13. shen-2017-nonredundant-rasgaps-abstract.md
14. sondermann-2019-rasgap-review-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Target identity: We focus on human RASA2 (UniProt Q15283), also known as GAP1m/GTPase-activating protein 1m. Literature classifies GAP1m/RASA2 among Ras-specific GAPs with a RasGAP catalytic domain and membrane-targeting/regulatory modules including C2 and PH domains, consistent with the UniProt-provided domain set (PH-like, PH, C2, RasGTPase/GAP) (scheffzek2019; conserved C2–GAP architecture augmenting catalytic function across RasGAPs) (scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14, paul2025thec2domain pages 4-6).

Key concepts and definitions
- Molecular function: RASA2 is a Ras GTPase-activating protein (RasGAP) that accelerates hydrolysis of Ras-GTP to Ras-GDP, thereby downregulating RAS output (e.g., RAF–MEK–ERK) in response to membrane signals. In T cells, RASA2 functions as an intracellular checkpoint that limits RAS/MAPK signalling upon antigen stimulation (Nature 2022) (https://doi.org/10.1038/s41586-022-05126-w; Aug 2022) (carnevale2022rasa2ablationin pages 1-2).
- Domains and mechanism: RasGAP family members, including GAP1m/RASA2, possess a catalytic RasGAP module and adjacent regulatory lipid-binding modules (C2 and PH) that help target and regulate activity at membranes. Recent structural work shows GAP-proximal C2 surfaces augment GAP catalytic activity; this architecture is conserved across C2-containing RasGAPs and underpins physiological regulation of Ras hydrolysis (https://doi.org/10.1073/pnas.2418433122; Feb 2025). Broader reviews detail RasGAP modular organization and mechanism (https://doi.org/10.1101/cshperspect.a031500; Aug 2019) (paul2025thec2domain pages 4-6, scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14).
- Substrate specificity: RASA2 is a Ras-specific GAP acting on the classical RAS isoforms to terminate RAS-GTP signalling; reviews of RAS–effector competition and GAP control detail how GAP activity influences effector engagement (e.g., RAF, PI3K) and localization (https://doi.org/10.1016/j.molcel.2024.06.027; Aug 2024; https://doi.org/10.3390/kinasesphosphatases1020007; Apr 2023) (mozzarelli2024functionalandstructural pages 6-7, nair2023regulationofrasgtpase pages 10-12).
- Cellular/localization context: PH and C2 domains confer lipid-dependent membrane association of RasGAPs, coordinating with the catalytic domain to accelerate Ras GTP hydrolysis at the plasma membrane/inner leaflet signalling sites (scheffzek2019; Paul 2025) (scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14, paul2025thec2domain pages 4-6).

Recent developments (prioritized 2023–2024)
- Melanoma genomics: In a real-world targeted DNA sequencing cohort of 254 cutaneous melanomas (2013–2023), RASA2 was recurrently altered (n=22; 8.7%), and NF1 mutations significantly co-occurred with RASA2 loss (Pearson r=0.37, adjusted p<0.001), supporting a tumor-suppressor role within MAPK pathway regulation and alignment with historic reports of RASA2 inactivation in melanoma (https://doi.org/10.3390/cancers16071347; Jan 2024; review context https://doi.org/10.3390/cancers12103066; Oct 2020) (haugh2024targeteddnasequencing pages 7-9, bellazzo2020cuttingthebrakes pages 15-17).
- Somatic SVs in melanoma: A harmonized analysis of melanoma structural variants (JCI 2024) highlighted recurrent pathway regulators including SPRED1 and RASA2 in certain subtypes, reinforcing the broader theme of Ras pathway negative regulators in melanoma; though details vary by subtype, the study supports biologic/therapeutic impact of noncanonical drivers (https://doi.org/10.1172/jci177270; May 2024) (haugh2024targeteddnasequencing pages 7-9).
- Radioresistance in NSCLC: A 2024 translational study linked high RASA2 to decreased radiotherapy response in NSCLC, proposing a mechanism whereby RASA2 binds p53, promotes its phosphorylation and ubiquitin–proteasome degradation, and thereby reduces apoptosis after irradiation (https://doi.org/10.21037/tlcr-24-160; Mar 2024) (li2024theroleof pages 1-3).
- RAS signalling context: A 2024 Molecular Cell review synthesizes how RAS–effector interactions and GAP-mediated inactivation shape pathway flux and localization, providing mechanistic context for how RASA2 loss elevates RAS-GTP and biases effector engagement (https://doi.org/10.1016/j.molcel.2024.06.027; Aug 2024). A 2023 review summarizes post-translational regulation of RAS and the roles of GAPs/GEFs in oncogenic signalling (https://doi.org/10.3390/kinasesphosphatases1020007; Apr 2023) (mozzarelli2024functionalandstructural pages 6-7, nair2023regulationofrasgtpase pages 10-12).

Current applications and implementations
- Engineered T cells/CAR-T (gene editing): Multiple screens and preclinical studies identify RASA2 as an intracellular checkpoint whose knockout enhances MAPK signalling, antigen sensitivity, cytolytic function, metabolic fitness, and persistence of engineered human T cells. The Nature 2022 study demonstrated improved tumor control across leukemia and solid tumor xenografts, with RASA2-KO CAR T cells outcompeting controls in bone marrow and conferring prolonged survival (https://doi.org/10.1038/s41586-022-05126-w; Aug 2022) (carnevale2022rasa2ablationin pages 8-9, carnevale2022rasa2ablationin pages 7-8).
- 2024 implementation reviews: Reviews in Biomarker Research (May 2024) and Leukemia (Oct 2024) summarize the use of CRISPR and base-editing to optimize CAR-T, explicitly noting RASA2 as a screen-derived intracellular checkpoint target for enhancing engineered T cell function and discussing manufacturing/delivery approaches (https://doi.org/10.1186/s40364-024-00602-z; https://doi.org/10.1038/s41375-024-02444-y) (song2024crisprcasbasedcartcells pages 7-9, lei2024leveragingcrisprgene pages 20-21).

Expert opinions and analysis
- Mechanistic positioning: Expert reviews (Cold Spring Harbor Perspectives in Medicine 2019; Molecular Cell 2024) emphasize that RasGAPs are modular, with lipid-binding domains (C2/PH) guiding subcellular targeting and augmenting catalysis, consistent with RASA2’s predicted architecture. The 2025 PNAS study provides direct evidence that the GAP-proximal C2 surface is functionally required to augment catalytic activity across RasGAPs, supporting the inference that RASA2’s C2 domain is critical for its physiological Ras inactivation role (https://doi.org/10.1101/cshperspect.a031500; https://doi.org/10.1016/j.molcel.2024.06.027; https://doi.org/10.1073/pnas.2418433122) (scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14, mozzarelli2024functionalandstructural pages 6-7, paul2025thec2domain pages 4-6).
- Safety considerations in T cell engineering: While RASA2 loss-of-function can enhance engineered T cells, RASA2 is a tumor suppressor recurrently altered in melanoma; therefore, experts suggest pairing edits with orthogonal safeguards (e.g., TRAC knock-in to eliminate endogenous TCR) and careful preclinical evaluation (Nature 2022; 2024 CAR-T engineering reviews) (carnevale2022rasa2ablationin pages 8-9, song2024crisprcasbasedcartcells pages 7-9, lei2024leveragingcrisprgene pages 20-21).

Relevant statistics and recent data
- Melanoma frequency/co-mutation: In the 254-patient cohort (2013–2023), RASA2 alterations were present in 22 cases (8.7%). NF1 significantly co-occurred with RASA2 loss (Pearson r=0.37, adjusted p<0.001), and triple-wild-type tumors sometimes harbored RASA2 as part of MAPK-pathway alterations, consistent with pathway dysregulation in melanoma (https://doi.org/10.3390/cancers16071347; Jan 2024) (haugh2024targeteddnasequencing pages 7-9).
- Engineered T cells (functional outcomes): RASA2 knockout T cells showed increased MAPK signalling, cytokine production, antigen-dim target killing, metabolic fitness, and in vivo competitive advantage with prolonged animal survival across models (Nature 2022), consolidated in 2024 reviews (carnevale2022rasa2ablationin pages 8-9, song2024crisprcasbasedcartcells pages 7-9, lei2024leveragingcrisprgene pages 20-21).
- NSCLC radioresistance association: In patient tumor analyses and orthotopic mouse models, higher RASA2 associated with lower ORR after radiotherapy and reduced apoptosis via p53 modulation (https://doi.org/10.21037/tlcr-24-160; Mar 2024) (li2024theroleof pages 1-3).

Pathway placement and cellular role
- Primary pathway: RASA2 negatively regulates the RAS–RAF–MEK–ERK cascade by accelerating Ras GTP hydrolysis; its lipid-binding domains coordinate membrane recruitment, ensuring spatial coupling of Ras inactivation with effector engagement. Loss or reduction of RASA2 increases RAS-GTP and downstream MAPK signalling, with context-specific effects on PI3K/other effectors depending on cellular localization and effector competition (Molecular Cell 2024; Kinases & Phosphatases 2023) (mozzarelli2024functionalandstructural pages 6-7, nair2023regulationofrasgtpase pages 10-12).

Study summary table (2023–2024 highlights)
| Year | Study / Type | Main finding about RASA2 | Disease / Context | URL | Publication date (month/year) |
|------|--------------|--------------------------|-------------------|-----|----------------------------|
| 2024 | Haugh et al. — Targeted DNA sequencing (Cancers) | RASA2 recurrently altered in cutaneous melanoma (n=22 in cohort); frequently co-mutated with NF1 and implicated in MAPK-pathway dysregulation (haugh2024targeteddnasequencing pages 7-9) | Cutaneous melanoma genomics | https://doi.org/10.3390/cancers16071347 | Jan 2024 |
| 2024 | Li et al. — Translational Lung Cancer Research | Elevated RASA2 linked to radioresistance via promotion of p53 phosphorylation/degradation and reduced apoptosis; high RASA2 associated with poorer radiotherapy response (li2024theroleof pages 1-3) | Non-small cell lung cancer (radioresistance) | https://doi.org/10.21037/tlcr-24-160 | Mar 2024 |
| 2024 | Song et al. — Review (Biomarker Research) | Summarizes CRISPR/Cas CAR-T engineering literature and notes RASA2 identified by CRISPR screens as an intracellular checkpoint whose KO enhances T cell MAPK signalling and cytotoxicity (song2024crisprcasbasedcartcells pages 7-9) | CAR-T engineering / immunotherapy | https://doi.org/10.1186/s40364-024-00602-z | May 2024 |
| 2024 | Lei et al. — Review (Leukemia) | Reviews CRISPR strategies to optimize CAR-T cells and highlights RASA2 as a screen-derived checkpoint target for improving engineered T cell function (lei2024leveragingcrisprgene pages 20-21) | CAR-T and leukemia applications | https://doi.org/10.1038/s41375-024-02444-y | Oct 2024 |
| 2024 | Mozzarelli et al. — Review (Molecular Cell) | Contextualizes Ras effector regulation and RasGAP function, supporting RASA2's role as a RasGAP that modulates RAS-MAPK signalling and localization (mozzarelli2024functionalandstructural pages 6-7) | RAS signalling biology / mechanism | https://doi.org/10.1016/j.molcel.2024.06.027 | Aug 2024 |

Table: Concise table summarizing major 2023–2024 publications on human RASA2 covering melanoma genomics, radioresistance, RAS signalling context, and CRISPR/CAR‑T engineering; each main finding includes a context citation for traceability.

Conclusion
Human RASA2 (Q15283) encodes a RasGAP with C2 and PH domains that localize/regulate its catalytic activity toward Ras, acting as a negative regulator of RAS–MAPK signalling at membranes. Recent genomics shows recurrent RASA2 alteration in melanoma with significant co-occurrence with NF1 loss, consistent with tumor-suppressor function. Emerging translational data link high RASA2 to radioresistance in NSCLC via p53 modulation. In cell therapy engineering, RASA2 knockout enhances CAR/TCR T cell antigen sensitivity, function, and persistence in preclinical models; 2024 reviews incorporate RASA2 among prioritized intracellular checkpoints for CRISPR engineering. Together, structural, mechanistic, and translational evidence position RASA2 as a membrane-localized RasGAP whose modulation has implications across oncology and engineered immunity (scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14, paul2025thec2domain pages 4-6, haugh2024targeteddnasequencing pages 7-9, li2024theroleof pages 1-3, carnevale2022rasa2ablationin pages 8-9, song2024crisprcasbasedcartcells pages 7-9, lei2024leveragingcrisprgene pages 20-21).

References

1. (scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14): Klaus Scheffzek and Giridhar Shivalingaiah. Ras-specific gtpase-activating proteins-structures, mechanisms, and interactions. Cold Spring Harbor perspectives in medicine, 9 3:a031500, Aug 2019. URL: https://doi.org/10.1101/cshperspect.a031500, doi:10.1101/cshperspect.a031500. This article has 104 citations and is from a peer-reviewed journal.

2. (paul2025thec2domain pages 4-6): Maxum E. Paul, Di Chen, Kimberly J. Vish, Nathaniel L. Lartey, Elizabeth Hughes, Zachary T. Freeman, Thomas L. Saunders, Amy L. Stiegler, Philip D. King, and Titus J. Boggon. The c2 domain augments ras gtpase-activating protein catalytic activity. Proceedings of the National Academy of Sciences of the United States of America, Feb 2025. URL: https://doi.org/10.1073/pnas.2418433122, doi:10.1073/pnas.2418433122. This article has 4 citations and is from a highest quality peer-reviewed journal.

3. (carnevale2022rasa2ablationin pages 1-2): Julia Carnevale, Eric Shifrut, Nupura Kale, William A. Nyberg, Franziska Blaeschke, Yan Yi Chen, Zhongmei Li, Sagar P. Bapat, Morgan E. Diolaiti, Patrick O’Leary, Shane Vedova, Julia Belk, Bence Daniel, Theodore L. Roth, Stefanie Bachl, Alejandro Allo Anido, Brooke Prinzing, Jorge Ibañez-Vega, Shannon Lange, Dalia Haydar, Marie Luetke-Eversloh, Maelys Born-Bony, Bindu Hegde, Scott Kogan, Tobias Feuchtinger, Hideho Okada, Ansuman T. Satpathy, Kevin Shannon, Stephen Gottschalk, Justin Eyquem, Giedre Krenciute, Alan Ashworth, and Alexander Marson. Rasa2 ablation in t cells boosts antigen sensitivity and long-term function. Nature, 609:174-182, Aug 2022. URL: https://doi.org/10.1038/s41586-022-05126-w, doi:10.1038/s41586-022-05126-w. This article has 209 citations and is from a highest quality peer-reviewed journal.

4. (mozzarelli2024functionalandstructural pages 6-7): Alessandro M. Mozzarelli, Dhirendra K. Simanshu, and Pau Castel. Functional and structural insights into ras effector proteins. Molecular Cell, 84:2807-2821, Aug 2024. URL: https://doi.org/10.1016/j.molcel.2024.06.027, doi:10.1016/j.molcel.2024.06.027. This article has 20 citations and is from a highest quality peer-reviewed journal.

5. (nair2023regulationofrasgtpase pages 10-12): Arathi Nair and Bhaskar Saha. Regulation of ras-gtpase signaling and localization by post-translational modifications. Kinases and Phosphatases, 1:97-116, Apr 2023. URL: https://doi.org/10.3390/kinasesphosphatases1020007, doi:10.3390/kinasesphosphatases1020007. This article has 5 citations.

6. (haugh2024targeteddnasequencing pages 7-9): Alexandra M. Haugh, Robert C. Osorio, Rony A. Francois, Michael E. Tawil, Katy K. Tsai, Michael Tetzlaff, Adil Daud, and Harish N. Vasudevan. Targeted dna sequencing of cutaneous melanoma identifies prognostic and predictive alterations. Cancers, Jan 2024. URL: https://doi.org/10.3390/cancers16071347, doi:10.3390/cancers16071347. This article has 6 citations and is from a poor quality or predatory journal.

7. (bellazzo2020cuttingthebrakes pages 15-17): Arianna Bellazzo and Licio Collavin. Cutting the brakes on ras—cytoplasmic gaps as targets of inactivation in cancer. Cancers, 12:3066, Oct 2020. URL: https://doi.org/10.3390/cancers12103066, doi:10.3390/cancers12103066. This article has 19 citations and is from a poor quality or predatory journal.

8. (li2024theroleof pages 1-3): Jie Li, Yan Zong, Zhan Tuo, Junwei Liu, and Jun Liu. The role of rasa2 in predicting radioresistance in lung cancer through regulation of p53. Translational Lung Cancer Research, 13:587-602, Mar 2024. URL: https://doi.org/10.21037/tlcr-24-160, doi:10.21037/tlcr-24-160. This article has 4 citations and is from a peer-reviewed journal.

9. (carnevale2022rasa2ablationin pages 8-9): Julia Carnevale, Eric Shifrut, Nupura Kale, William A. Nyberg, Franziska Blaeschke, Yan Yi Chen, Zhongmei Li, Sagar P. Bapat, Morgan E. Diolaiti, Patrick O’Leary, Shane Vedova, Julia Belk, Bence Daniel, Theodore L. Roth, Stefanie Bachl, Alejandro Allo Anido, Brooke Prinzing, Jorge Ibañez-Vega, Shannon Lange, Dalia Haydar, Marie Luetke-Eversloh, Maelys Born-Bony, Bindu Hegde, Scott Kogan, Tobias Feuchtinger, Hideho Okada, Ansuman T. Satpathy, Kevin Shannon, Stephen Gottschalk, Justin Eyquem, Giedre Krenciute, Alan Ashworth, and Alexander Marson. Rasa2 ablation in t cells boosts antigen sensitivity and long-term function. Nature, 609:174-182, Aug 2022. URL: https://doi.org/10.1038/s41586-022-05126-w, doi:10.1038/s41586-022-05126-w. This article has 209 citations and is from a highest quality peer-reviewed journal.

10. (carnevale2022rasa2ablationin pages 7-8): Julia Carnevale, Eric Shifrut, Nupura Kale, William A. Nyberg, Franziska Blaeschke, Yan Yi Chen, Zhongmei Li, Sagar P. Bapat, Morgan E. Diolaiti, Patrick O’Leary, Shane Vedova, Julia Belk, Bence Daniel, Theodore L. Roth, Stefanie Bachl, Alejandro Allo Anido, Brooke Prinzing, Jorge Ibañez-Vega, Shannon Lange, Dalia Haydar, Marie Luetke-Eversloh, Maelys Born-Bony, Bindu Hegde, Scott Kogan, Tobias Feuchtinger, Hideho Okada, Ansuman T. Satpathy, Kevin Shannon, Stephen Gottschalk, Justin Eyquem, Giedre Krenciute, Alan Ashworth, and Alexander Marson. Rasa2 ablation in t cells boosts antigen sensitivity and long-term function. Nature, 609:174-182, Aug 2022. URL: https://doi.org/10.1038/s41586-022-05126-w, doi:10.1038/s41586-022-05126-w. This article has 209 citations and is from a highest quality peer-reviewed journal.

11. (song2024crisprcasbasedcartcells pages 7-9): Ping Song, Qiqi Zhang, Zhiyong Xu, Yuelin Shi, Ruirui Jing, and Dingcun Luo. Crispr/cas-based car-t cells: production and application. Biomarker Research, May 2024. URL: https://doi.org/10.1186/s40364-024-00602-z, doi:10.1186/s40364-024-00602-z. This article has 34 citations and is from a peer-reviewed journal.

12. (lei2024leveragingcrisprgene pages 20-21): Tao Lei, Yazhuo Wang, Yuchen Zhang, Yufei Yang, Jiaying Cao, Jiansong Huang, Jiali Chen, Huajing Chen, Jiayi Zhang, Luzheng Wang, Xinjie Xu, Robert Peter Gale, and Liang Wang. Leveraging crispr gene editing technology to optimize the efficacy, safety and accessibility of car t-cell therapy. Leukemia, 38:2517-2543, Oct 2024. URL: https://doi.org/10.1038/s41375-024-02444-y, doi:10.1038/s41375-024-02444-y. This article has 69 citations and is from a highest quality peer-reviewed journal.

Citations

1. haugh2024targeteddnasequencing pages 7-9
2. li2024theroleof pages 1-3
3. song2024crisprcasbasedcartcells pages 7-9
4. lei2024leveragingcrisprgene pages 20-21
5. mozzarelli2024functionalandstructural pages 6-7
6. scheffzek2019rasspecificgtpaseactivatingproteinsstructures pages 12-14
7. nair2023regulationofrasgtpase pages 10-12
8. bellazzo2020cuttingthebrakes pages 15-17
9. https://doi.org/10.1038/s41586-022-05126-w;
10. https://doi.org/10.1073/pnas.2418433122;
11. https://doi.org/10.1101/cshperspect.a031500;
12. https://doi.org/10.1016/j.molcel.2024.06.027;
13. https://doi.org/10.3390/kinasesphosphatases1020007;
14. https://doi.org/10.3390/cancers16071347;
15. https://doi.org/10.3390/cancers12103066;
16. https://doi.org/10.1172/jci177270;
17. https://doi.org/10.21037/tlcr-24-160;
18. https://doi.org/10.1186/s40364-024-00602-z;
19. https://doi.org/10.1038/s41375-024-02444-y
20. https://doi.org/10.1073/pnas.2418433122
21. https://doi.org/10.3390/cancers16071347
22. https://doi.org/10.21037/tlcr-24-160
23. https://doi.org/10.1186/s40364-024-00602-z
24. https://doi.org/10.1016/j.molcel.2024.06.027
25. https://doi.org/10.1101/cshperspect.a031500,
26. https://doi.org/10.1073/pnas.2418433122,
27. https://doi.org/10.1038/s41586-022-05126-w,
28. https://doi.org/10.1016/j.molcel.2024.06.027,
29. https://doi.org/10.3390/kinasesphosphatases1020007,
30. https://doi.org/10.3390/cancers16071347,
31. https://doi.org/10.3390/cancers12103066,
32. https://doi.org/10.21037/tlcr-24-160,
33. https://doi.org/10.1186/s40364-024-00602-z,
34. https://doi.org/10.1038/s41375-024-02444-y,

Functional Annotation of Human RASA2 (Q15283)

Gene and Protein Overview

RASA2 (RAS p21 protein activator 2, UniProt Q15283) is a human gene encoding a Ras GTPase-activating protein (Ras GAP) that turns off Ras signaling by accelerating the hydrolysis of Ras-bound GTP (pmc.ncbi.nlm.nih.gov). The RASA2 protein belongs to the GAP1 family of Ras GAPs and is sometimes referred to by the alias GAP1(m) (www.ncbi.nlm.nih.gov). By enhancing Ras’s weak intrinsic GTPase activity, RASA2 promotes conversion of active Ras–GTP to inactive Ras–GDP, thereby suppressing Ras function (www.ncbi.nlm.nih.gov). This “off-switch” role allows RASA2 to control downstream signaling pathways that drive cell proliferation and differentiation (www.ncbi.nlm.nih.gov). Importantly, RASA2 stimulates GTP hydrolysis on normal Ras (p21) but is ineffective on certain oncogenic Ras mutants (e.g. Ras^G12V), which are resistant to GAPs (www.ncbi.nlm.nih.gov). In essence, RASA2 is a negative regulator of Ras, helping maintain appropriate Ras activity levels in cells.

Protein Structure and Localization

The RASA2 protein is a multi-domain cytosolic protein that can associate with the inner surface of the plasma membrane in response to signaling cues. It has a conserved C-terminal RasGAP domain responsible for its catalytic activity, and N-terminal regulatory domains typical of the GAP1 family (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, RASA2 contains two tandem C2 domains (calcium-dependent phospholipid-binding domains) and a pleckstrin homology (PH) domain, also known as a BTK-type PH domain (pmc.ncbi.nlm.nih.gov). These domains mediate lipid binding and subcellular targeting: for example, the PH domains of RASA2 and its close relative RASA3 bind strongly to the membrane lipid phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) (pmc.ncbi.nlm.nih.gov). In fact, high-resolution pull-down experiments identified RASA2 as a PIP₃-binding protein, indicating that RASA2 is recruited to PIP₃-enriched membranes (such as activated receptor signaling sites) (pmc.ncbi.nlm.nih.gov). The C2 domains can bind membranes in a Ca²⁺-dependent manner, suggesting that calcium signals may also promote RASA2 membrane localization (pmc.ncbi.nlm.nih.gov). Together, these domains allow RASA2 to shuttle from the cytosol to the plasma membrane where its substrate Ras resides. RASA2 lacks transmembrane regions and is not secreted; it functions inside the cell, with its activity occurring at the cytosol–inner membrane interface. Consistent with a general signaling role, RASA2 is broadly expressed across tissues, with particularly notable expression in immune and lymphoid organs (www.ncbi.nlm.nih.gov). This widespread distribution reflects its fundamental role in regulating Ras signals in many cell types.

Biochemical Function and Mechanism

As a Ras GTPase-activating protein, RASA2’s primary biochemical function is to catalyze the inactivation of Ras by accelerating Ras’s GTPase activity. Ras proteins are molecular switches that toggle between an active GTP-bound state and an inactive GDP-bound state. RASA2 binds to active Ras–GTP and inserts a “catalytic arginine finger” into Ras’s active site, greatly accelerating GTP hydrolysis (pmc.ncbi.nlm.nih.gov). In the human RASA2 protein, the critical arginine residue is Arg-511, which is contributed into the Ras catalytic site to stimulate GTP cleavage to GDP (pmc.ncbi.nlm.nih.gov). This mechanism is analogous to other Ras GAPs (such as p120^RasGAP/RASA1 and neurofibromin), whereby the GAP protein provides an arginine residue that complements Ras’s active-site chemistry and induces GTP breakdown (pmc.ncbi.nlm.nih.gov). Through this enzymatic action, RASA2 converts Ras-GTP (active) to Ras-GDP (inactive), effectively terminating the Ras signal. The “substrate” of RASA2 is Ras (primarily H-Ras, N-Ras, K-Ras and related small GTPases in the Ras subfamily) in its GTP-bound form. RASA2 shows specificity for normal (wild-type) Ras and does not effectively stimulate hydrolysis on mutant Ras proteins that carry activating oncogenic mutations (www.ncbi.nlm.nih.gov). Some GAP1 family members are known to act on the Ras-related GTPase Rap1 as well as Ras (pmc.ncbi.nlm.nih.gov); however, RASA2 is chiefly a Ras-specific GAP in physiological contexts, whereas the related RASA3 (GAP1^IP4BP) predominantly inactivates Rap1 (pmc.ncbi.nlm.nih.gov). By turning off Ras, RASA2 attenuates downstream signaling cascades initiated by Ras, most prominently the RAF–MEK–ERK (MAP kinase) pathway which controls cell growth and differentiation. In this way, RASA2 acts as a molecular brake in signaling pathways that require timely shutdown of Ras activity.

Biological Role in Signaling Pathways

RASA2 plays a critical role in regulating Ras-dependent signaling pathways, thereby influencing various cellular processes. Ras activation is a key step in pathways downstream of many receptors (e.g. growth factor receptors, cytokine receptors, antigen receptors), leading to outcomes such as proliferation, differentiation, and survival. RASA2 provides negative feedback in these pathways by ensuring that Ras activation is transient and appropriately scaled. For example, in growth factor signaling, receptor tyrosine kinases activate Ras (via Ras GEFs like SOS or RasGRP), and RASA2 can bind to the membrane (through its PH domain binding PIP₃ generated by receptor-activated PI3K) to inactivate Ras and terminate the signal (pmc.ncbi.nlm.nih.gov). This feedback loop prevents over-activation of the Ras–MAPK cascade, thereby maintaining normal control of cell proliferation. Consistently, loss of RASA2 leads to prolonged or enhanced Ras signaling, which can drive excessive cell growth and other aberrant behaviors (pmc.ncbi.nlm.nih.gov).

One well-studied context for RASA2 function is in T lymphocyte signaling. Ras activation is essential for T-cell receptor (TCR) signaling, leading to downstream ERK/MAPK activation important for T cell proliferation and activation. Recent genetic screens in primary human T cells identified RASA2 as a crucial “brake” on TCR signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). RASA2 is expressed in both CD4⁺ and CD8⁺ T cells (pmc.ncbi.nlm.nih.gov), and when T cells are stimulated via the TCR, RASA2 normally acts to limit Ras activity and downstream activation. In experiments using CRISPR/Cas9 knockout, loss of RASA2 resulted in a roughly 2-fold increase in T cell proliferation upon stimulation, along with upregulation of activation markers (such as CD69 and CD154) (pmc.ncbi.nlm.nih.gov). RASA2-deficient T cells also showed enhanced functional outcomes – for instance, T cells lacking RASA2 had heightened sensitivity to antigen and killed target cancer cells more efficiently in co-culture assays (pmc.ncbi.nlm.nih.gov). Notably, RASA2 knockout T cells proliferated more robustly even under typically suppressive conditions (presence of immunosuppressive factors like adenosine, TGF-β, or regulatory T cells) (pmc.ncbi.nlm.nih.gov). These findings demonstrate that RASA2 serves as a gatekeeper in the TCR signaling pathway, restraining Ras/MAPK pathway activation to keep T cell responses in check (pmc.ncbi.nlm.nih.gov). When RASA2 is removed, Ras signaling goes unchecked, resulting in hyperactive T cell responses. This precise role in T cells exemplifies how RASA2 functions in signaling pathways: by dampening Ras activity, it modulates the magnitude of downstream biological responses (in this case, cell proliferation and effector function). Such negative regulation is crucial for maintaining immune homeostasis and preventing over-activation.

Beyond T cells, RASA2 is thought to perform a similar homeostatic role in other cell types. It contributes to controlling Ras-dependent pathways in development and differentiation. Indeed, germline mutations in RASA2 have been identified in Noonan syndrome, a developmental disorder (Rasopathy) caused by hyperactive Ras/MAPK signaling (pmc.ncbi.nlm.nih.gov). Although RASA2 mutations appear to be a rare cause of Noonan syndrome, their occurrence underscores that RASA2’s regulatory function is important in normal human development – loss of RASA2 can elevate Ras signaling enough to produce developmental abnormalities (pmc.ncbi.nlm.nih.gov). In summary, RASA2 operates in multiple signaling contexts as a negative regulator: it ensures that Ras-driven pathways (like the MAPK cascade) are properly shut off, thereby influencing cell proliferation, differentiation, and activation in a tightly controlled manner.

Structural Features and Regulatory Interactions

The multi-domain structure of RASA2 hints at mechanisms by which its activity is regulated within the cell. The pleckstrin homology (PH) domain of RASA2 binds membrane phosphoinositides, especially PIP₃, with high affinity (pmc.ncbi.nlm.nih.gov). This means that when PI3K enzymes produce PIP₃ (for instance, during receptor signaling), RASA2 can be recruited to the plasma membrane via its PH domain. Co-localization at the membrane brings RASA2 into proximity with active Ras, enabling it to inactivate Ras at the site of signal transduction. Thus, PIP₃ acts as a docking signal for RASA2, coupling PI3K activation to Ras signal termination. This is a form of crosstalk between the PI3K pathway and Ras pathway: the generation of PIP₃ not only triggers AKT signaling but also helps initiate negative feedback on Ras through RASA2’s recruitment (pmc.ncbi.nlm.nih.gov).

The tandem C2 domains in RASA2 likely mediate additional regulatory interactions. C2 domains typically bind acidic phospholipids in a calcium-dependent manner. While RASA2’s C2 domains have not been studied as extensively as those of RASA4/CAPRI (a calcium-promoted Ras GAP), their presence suggests that calcium fluxes might enhance RASA2’s membrane association or activity. For example, analogies to RASA4 (which translocates to the membrane upon Ca²⁺ signals) raise the possibility that RASA2 could respond to Ca²⁺ increases by a similar mechanism (pmc.ncbi.nlm.nih.gov). In combination, the PH and C2 domains position RASA2 as a signal-responsive inhibitor: it integrates second messengers (like lipid products and Ca²⁺) to modulate when and where it turns off Ras. Structurally, RASA2 does not contain SH2 or SH3 domains (domains found in some other Ras regulators like RASA1/p120^RasGAP), so it may not directly bind phosphotyrosine sites on receptors. Instead, RASA2 relies on lipid-binding for localization, and potentially partners with other proteins via its PH/C2 regions or other motifs. There is evidence that RASA2 can form signaling complexes at the membrane; for instance, earlier studies showed that the closely related GAP1 family member (RASA3) binds inositol 1,3,4,5-tetrakisphosphate (IP₄) and PIP₂, suggesting complex regulatory ligand interactions (pmc.ncbi.nlm.nih.gov). RASA2’s PH domain, in particular, shows specificity for PIP₃, which may distinguish its recruitment profile from RASA3 or RASAL1 (pmc.ncbi.nlm.nih.gov).

On the enzymatic side, RASA2’s activity can be inferred to be subject to feedback regulation. When Ras is active, one of its downstream effects is to activate PI3K, raising PIP₃ levels; this in turn recruits RASA2 to dampen Ras – a negative feedback loop. Conversely, if Ras signaling is minimal, RASA2 may remain diffuse in the cytosol (less membrane-bound). This dynamic localization has been observed for similar GAP1 family proteins. In addition, post-translational modifications could regulate RASA2 (though specific modifications are not well characterized in literature as of current knowledge). By analogy, other Ras GAPs are known to be phosphorylated or cleaved in certain conditions (pmc.ncbi.nlm.nih.gov). One example in the broader GAP family: caspase-3 can cleave p120^RasGAP (RASA1) during apoptosis, enhancing Ras signaling in dying cells (pmc.ncbi.nlm.nih.gov). It’s reported that a point mutation preventing a RasGAP’s cleavage led to prolonged Ras activity (pmc.ncbi.nlm.nih.gov). Whether RASA2 undergoes similar regulatory phosphorylation or proteolysis remains to be fully explored, but these are potential layers of control. In summary, RASA2’s function is tightly linked to its structural domains: the PH and C2 domains target it to the membrane in response to lipid/Ca²⁺ signals, and the GAP domain then executes Ras inactivation. This design ensures RASA2 is activated at the right place and time to modulate Ras signaling.

Physiological and Clinical Significance

RASA2 is vital for normal cellular homeostasis, and its dysfunction has been implicated in human diseases that center on aberrant Ras signaling. Here are key contexts in which RASA2’s role has been highlighted:

• Tumor Suppressor in Cancer: RASA2 has emerged as a tumor suppressor gene, particularly in melanoma. A large-scale sequencing of 501 melanomas identified recurrent inactivating mutations in RASA2 in about 5% of melanoma tumors (pmc.ncbi.nlm.nih.gov). Many of these mutations are nonsense or frameshift changes predicted to eliminate RASA2 function (pmc.ncbi.nlm.nih.gov). Functional studies showed that loss of RASA2 leads to enhanced Ras–ERK signaling in melanoma cells, driving increased cell proliferation, survival, and cell migration (pmc.ncbi.nlm.nih.gov). In cell-based assays, reintroducing RASA2 or restoring its function curbed melanoma cell growth and motility, consistent with Ras pathway suppression (pmc.ncbi.nlm.nih.gov). Clinically, RASA2 protein expression is absent or greatly reduced in a significant fraction of melanomas – at least 30% of cases show loss of RASA2 expression, often due to gene deletion or epigenetic silencing (pmc.ncbi.nlm.nih.gov). Importantly, melanoma patients whose tumors lack RASA2 tend to have worse outcomes, suggesting that RASA2 loss confers a more aggressive, Ras-driven disease course (pmc.ncbi.nlm.nih.gov). These findings (Arafeh et al., Nat. Genet., 2015) establish that disabling RASA2 is one way tumors achieve unchecked Ras activity. In other cancers, RASA2 mutations are less frequent but have been observed. For instance, loss-of-function RASA2 variants have been noted in some lung cancers and colon cancers (often alongside other Ras pathway alterations), although detailed frequencies are still being investigated (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The unifying theme is that cancer cells can inactivate RASA2 to escape its restraining effect on Ras, thereby gaining a growth advantage. RASA2’s status as a tumor suppressor places it among several Ras pathway negative regulators (like NF1, RASA1, and SPRED1) that are mutated in cancers to enable hyperactive Ras signaling.

• Rasopathies and Developmental Disorders: Germline mutations in the Ras/MAPK pathway cause a group of developmental syndromes known as Rasopathies. Noonan syndrome is one such condition, typically arising from mutations in genes like PTPN11 (SHP2), SOS1, KRAS/NRAS, or RAF1. Notably, rare mutations in RASA2 have also been found in Noonan syndrome patients (pmc.ncbi.nlm.nih.gov). A 2014 genomic study identified RASA2 variants in individuals with Noonan syndrome who did not have the more common mutations (pmc.ncbi.nlm.nih.gov). These RASA2 mutations likely reduce RASA2 function, leading to elevated Ras activity during development – consistent with the Noonan phenotype of cardiac, facial, and growth abnormalities caused by Ras/MAPK overactivation. While RASA2 mutations account for only a small subset of Rasopathy cases, their identification underscores the gene’s importance: even partial loss of RASA2’s Ras-GAP activity in germline can disturb developmental signaling balance. It also expands the spectrum of Ras regulators whose integrity is required for normal human development. Researchers continue to study such RASA2 variants to understand tissue-specific effects (for example, why certain developmental pathways are sensitive to Ras hyperactivity when RASA2 is deficient).

• Immune Regulation and Immunotherapy: The discovery of RASA2’s role in T cells has implications for immunology and cancer immunotherapy. As discussed, RASA2 keeps T cell activation in check by dampening Ras signals. In conditions like chronic infections or cancer, T cells often become “exhausted” or less responsive, partly due to inhibitory pathways. There is emerging interest in targeting RASA2 to boost T cell responses in therapies. A 2022 study demonstrated that knocking out RASA2 in human T cells can enhance their proliferation and function over the long term, improving the cells’ ability to attack cancer cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These RASA2-deficient T cells showed greater sensitivity to low levels of antigen, meaning they could respond to tumor cells that express low amounts of target, an important feature for solid tumor immunotherapy (pmc.ncbi.nlm.nih.gov). In a preclinical model, adoptive transfer of RASA2-knockout T cells led to improved tumor control in mice, indicating that inhibiting RASA2 can strengthen anti-tumor immunity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Based on expert analysis, RASA2 is considered a promising target to modulate T cell activity: by pharmacologically inhibiting RASA2 or using gene-editing to disable it, one might reinvigorate T cells to better fight cancers (pmc.ncbi.nlm.nih.gov). Indeed, researchers have suggested that transient RASA2 inhibition could enhance T cell-based therapies (such as CAR-T cells or TCR-transduced T cells) especially against solid tumors where T cell responses are often suboptimal (pmc.ncbi.nlm.nih.gov). It should be noted, however, that any approach to inhibit RASA2 systemically must be cautious – since RASA2 is a tumor suppressor in some contexts, completely blocking it in patients could carry a risk of unintended Ras overactivation in healthy cells (pmc.ncbi.nlm.nih.gov). To circumvent this, strategies might focus on ex vivo RASA2 knock-out in T cells (engineering patient T cells to remove RASA2 before infusing them back, so the effect is restricted to the therapeutic cells) (pmc.ncbi.nlm.nih.gov). This area is an active topic of research and represents a real-world implementation of RASA2 functional insights: the gene, once identified as a brake on immune cells, is now a candidate handle for boosting immunotherapy.

• Drug Resistance Mechanisms: In cancer therapy, tumors often develop resistance to targeted drugs. Interestingly, loss of negative regulators like RASA2 can be a mechanism of resistance to inhibitors that act upstream of Ras. For example, SHP2 inhibitors are drugs that block an upstream activator of Ras (SHP2 is needed for efficient Ras–GEF function). Recent CRISPR screens in cancer cell lines found that knocking out RASA2 confers resistance to SHP2 inhibition – without RASA2, Ras remains more active even when SHP2 is blocked (pmc.ncbi.nlm.nih.gov). In these screens, RASA2 was among the top “hits” whose deletion led to sustained ERK pathway activation despite the presence of SHP2 inhibitor (pmc.ncbi.nlm.nih.gov). This result aligns with the idea that if a tumor loses RASA2, it becomes less dependent on SHP2 or other upstream signals to keep Ras active (since Ras is intrinsically more active due to lack of GAP activity). Thus, RASA2 status could influence how tumors respond to certain therapies. Tumors with RASA2 loss-of-function might be intrinsically resistant to drugs that rely on normal Ras regulation. These insights are guiding precision medicine approaches – for instance, screening melanomas or other cancers for RASA2 mutations might help predict responsiveness to MAPK pathway inhibitors or combination therapies. More broadly, it highlights RASA2 as a node in the Ras network that, when removed, alters signaling fidelity and drug sensitivity.

Expert Commentary and Current Research Directions

Experts regard RASA2 as an important regulatory hub in Ras signaling, with roles that bridge fundamental biochemistry and clinical relevance. A 2023 review in Trends in Immunology dubbed RASA2 (and its Rap-GAP counterpart RASA3) “gatekeepers” of T cell activation and adhesion (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), emphasizing that these GAPs maintain immune cells in a quiescent state until appropriate activation is needed. The authors note that genetic screens have firmly placed RASA2 as a key limiting factor in T cell responses (pmc.ncbi.nlm.nih.gov). They discuss the exciting possibility of manipulating RASA2 for therapy – for example, inhibiting RASA2 to enhance T cell attack on cancers, or conversely activating/augmenting RASA2 to tone down immune activation in autoimmunity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Such ideas are built on solid experimental evidence (e.g. CRISPR studies) and represent a new direction in immunotherapy research. At the same time, cancer biologists have pointed out the significance of RASA2 in tumors lacking direct Ras mutations. Since Ras itself is hard to target with drugs (aside from specific mutants like KRAS^G12C), restoring or mimicking RASA2 function could be a strategy to suppress Ras activity in tumors. However, reactivating a lost tumor suppressor is challenging – thus, current research is more focused on understanding the pathways affected by RASA2 loss and finding synthetic lethal interactions. For instance, if a tumor loses RASA2, it might become particularly dependent on other signaling nodes that could be drugged. One study noted that RASA2 loss in melanoma often co-occurs with certain RAF or MEK pathway alterations, implying these tumors heavily rely on the MAPK cascade for growth (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This suggests that such tumors might respond well to MEK or ERK inhibitors, a hypothesis under investigation.

Structurally, ongoing research aims to resolve the three-dimensional structure of RASA2’s domains and their complexes with Ras, to better understand how exactly RASA2 engages Ras at membranes. While Ras–GAP interactions have been visualized for other GAPs (like p120^RasGAP and neurofibromin) (pmc.ncbi.nlm.nih.gov), RASA2 has unique regulatory domains whose conformational changes (perhaps upon binding PIP₃ or Ca²⁺) are of great interest. Bioinformatic analyses show that RASA2 and its GAP1 family homologs are evolutionarily conserved in vertebrates and share significant homology, hinting that insights from one (e.g. RASA3’s interaction with phosphoinositides) can inform understanding of another. There is also interest in evolutionary biology of Ras GAPs: RASA2 might have arisen to provide fine-tuned control of Ras in specialized contexts (potentially relating to the immune system, given its prominent expression there). Comparative studies in mice have indicated that Rasa2 deficiency can enhance immune responses (as seen in T cell studies), and future work may create Rasa2-knockout animal models to observe any spontaneous disease or predisposition (e.g. cancer incidence or autoimmune phenotypes) arising from chronic Ras hyperactivity.

In summary, RASA2 is recognized as a key functional node in the Ras signaling network, coupling membrane second messengers to the termination of Ras activity. Its primary role is enzymatic: stimulating GTP hydrolysis on Ras to shut Ras off at the right time and place. Through this function, it safeguards cells from excessive Ras signaling, thereby influencing processes like proliferation, migration, and immune cell activation. The protein localizes to the cytosol and inner plasma membrane, guided by its PH and C2 domains, ensuring it acts in proximity to Ras. Disruption of RASA2 has tangible biological consequences – from hyperactive T cells to aggressive tumor behavior – underscoring why nature has conserved this Ras regulator. Current research (2023–2024) continues to unravel the nuances of RASA2’s regulation and to exploit its function in clinical applications, whether by targeting it in immunotherapy or considering its status in cancer treatment decisions. All evidence to date solidifies the view of RASA2 as an essential “off-switch” for Ras, crucial for balanced signaling and normal cellular function (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

References: (Publication dates and sources are included in citations)

Citations

1. AnnotationURLCitation(end_index=445, start_index=284, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20and%20RASA3%2C%20which%20are,T%20cell%20activation%20and%20migration')
2. AnnotationURLCitation(end_index=706, start_index=558, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=Also%20known%20as%20GAP1M%20Summary,form%20of%20RAS%2C%20thereby%20allowing')
3. AnnotationURLCitation(end_index=1011, start_index=861, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=Summary%20The%20protein%20encoded%20by,provided%20by%20RefSeq%2C%20Dec%202014')
4. AnnotationURLCitation(end_index=1290, start_index=1140, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=Summary%20The%20protein%20encoded%20by,provided%20by%20RefSeq%2C%20Dec%202014')
5. AnnotationURLCitation(end_index=1608, start_index=1458, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=Summary%20The%20protein%20encoded%20by,provided%20by%20RefSeq%2C%20Dec%202014')
6. AnnotationURLCitation(end_index=2224, start_index=2063, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=domain%20structures%2C%20including%20GAP%20domains,The%20RASA3%20PH%20domain')
7. AnnotationURLCitation(end_index=2334, start_index=2225, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=A,through%20a%20distinct')
8. AnnotationURLCitation(end_index=2674, start_index=2513, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=domain%20structures%2C%20including%20GAP%20domains,The%20RASA3%20PH%20domain')
9. AnnotationURLCitation(end_index=3022, start_index=2895, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=which%20includes%20RASAL1%20,4%7D%29%20and')
10. AnnotationURLCitation(end_index=3383, start_index=3222, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=domain%20structures%2C%20including%20GAP%20domains,The%20RASA3%20PH%20domain')
11. AnnotationURLCitation(end_index=3685, start_index=3524, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=domain%20structures%2C%20including%20GAP%20domains,The%20RASA3%20PH%20domain')
12. AnnotationURLCitation(end_index=4245, start_index=4121, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=The%20protein%20encoded%20by%20this,9%29%20and%2024')
13. AnnotationURLCitation(end_index=4917, start_index=4799, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=B%29%20RAS,through%20a%20distinct')
14. AnnotationURLCitation(end_index=5184, start_index=5075, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=A,through%20a%20distinct')
15. AnnotationURLCitation(end_index=5512, start_index=5403, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=A,through%20a%20distinct')
16. AnnotationURLCitation(end_index=6090, start_index=5940, title='RASA2 RAS p21 protein activator 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/5922#:~:text=Summary%20The%20protein%20encoded%20by,provided%20by%20RefSeq%2C%20Dec%202014')
17. AnnotationURLCitation(end_index=6310, start_index=6180, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=Several%20RAS,specific%20GAPs%20%5B%2041%2C54')
18. AnnotationURLCitation(end_index=6619, start_index=6458, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20and%20RASA3%2C%20which%20are,T%20cell%20activation%20and%20migration')
19. AnnotationURLCitation(end_index=7832, start_index=7705, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=which%20includes%20RASAL1%20,4%7D%29%20and')
20. AnnotationURLCitation(end_index=8274, start_index=8106, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=%5B104%5D.%20Furthermore%2C%20loss,the%20Ras%20signaling%20pathway%2C%20potentially')
21. AnnotationURLCitation(end_index=8744, start_index=8617, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=Repeats,these%20GAPs%2C%20how%20they%20are')
22. AnnotationURLCitation(end_index=8841, start_index=8745, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=,Figure%201')
23. AnnotationURLCitation(end_index=9038, start_index=8894, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L349%20,in%20T%20cells%20remained%20unexplored')
24. AnnotationURLCitation(end_index=9488, start_index=9368, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L356%20Figure%202A,TCR')
25. AnnotationURLCitation(end_index=9830, start_index=9704, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L360%20antibodies%20in,2%2C3')
26. AnnotationURLCitation(end_index=10190, start_index=10020, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L373%20succinimidyl%20ester,reg%7D%20cells%20%5B2%2C3%5D.%20Cells%20were')
27. AnnotationURLCitation(end_index=10488, start_index=10361, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=Repeats,these%20GAPs%2C%20how%20they%20are')
28. AnnotationURLCitation(end_index=11426, start_index=11265, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20was%20identified%20as%20an,defects%20and%20elevated%20RAS%20activity')
29. AnnotationURLCitation(end_index=11851, start_index=11690, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20was%20identified%20as%20an,defects%20and%20elevated%20RAS%20activity')
30. AnnotationURLCitation(end_index=12531, start_index=12404, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=which%20includes%20RASAL1%20,4%7D%29%20and')
31. AnnotationURLCitation(end_index=13267, start_index=13140, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=which%20includes%20RASAL1%20,4%7D%29%20and')
32. AnnotationURLCitation(end_index=13991, start_index=13830, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=domain%20structures%2C%20including%20GAP%20domains,The%20RASA3%20PH%20domain')
33. AnnotationURLCitation(end_index=14939, start_index=14797, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=affinity%20for%20PI%283%2C4%2C5%29P_,2%7D%20%5B%2050%2C32')
34. AnnotationURLCitation(end_index=15204, start_index=15070, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=which%20includes%20RASAL1%20,2%7D%20%5B%2050%2C32')
35. AnnotationURLCitation(end_index=16077, start_index=15910, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=Mutations%20in%20RASGAPs%20also%20play,of%20RASGAPs%20promote%20tumorigenesis%20by')
36. AnnotationURLCitation(end_index=16383, start_index=16216, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=Mutations%20in%20RASGAPs%20also%20play,of%20RASGAPs%20promote%20tumorigenesis%20by')
37. AnnotationURLCitation(end_index=16649, start_index=16482, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=Mutations%20in%20RASGAPs%20also%20play,of%20RASGAPs%20promote%20tumorigenesis%20by')
38. AnnotationURLCitation(end_index=17762, start_index=17609, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Analysis%20of%20501%20melanoma%20exomes,of%20Ras%20GAPs%20in%20cancer')
39. AnnotationURLCitation(end_index=18027, start_index=17861, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=mutations%20encompass%20at%20least%2020,the%20CytoScan%20High%20Definition%20array')
40. AnnotationURLCitation(end_index=18353, start_index=18200, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Analysis%20of%20501%20melanoma%20exomes,of%20Ras%20GAPs%20in%20cancer')
41. AnnotationURLCitation(end_index=18658, start_index=18505, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Analysis%20of%20501%20melanoma%20exomes,of%20Ras%20GAPs%20in%20cancer')
42. AnnotationURLCitation(end_index=19028, start_index=18875, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Analysis%20of%20501%20melanoma%20exomes,of%20Ras%20GAPs%20in%20cancer')
43. AnnotationURLCitation(end_index=19355, start_index=19198, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Analysis%20of%20501%20melanoma%20exomes,importance%20of%20Ras%20GAPs%20in')
44. AnnotationURLCitation(end_index=19948, start_index=19781, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=Mutations%20in%20RASGAPs%20also%20play,of%20RASGAPs%20promote%20tumorigenesis%20by')
45. AnnotationURLCitation(end_index=20118, start_index=19949, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=cell%20lung%20cancer%20,pathological%20implications%20in%20urological%20malignancies')
46. AnnotationURLCitation(end_index=20992, start_index=20831, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20was%20identified%20as%20an,defects%20and%20elevated%20RAS%20activity')
47. AnnotationURLCitation(end_index=21245, start_index=21122, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=%2A%2039.Chen%20P,PMC%20free%20article')
48. AnnotationURLCitation(end_index=22771, start_index=22651, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L356%20Figure%202A,TCR')
49. AnnotationURLCitation(end_index=22898, start_index=22772, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L360%20antibodies%20in,2%2C3')
50. AnnotationURLCitation(end_index=23240, start_index=23116, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=,cells%20during%20exhaustion%20and%20in')
51. AnnotationURLCitation(end_index=23545, start_index=23421, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=,cells%20during%20exhaustion%20and%20in')
52. AnnotationURLCitation(end_index=23700, start_index=23546, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L215%20adoptive%20cell,T%20cell%20responses%20in%20mouse')
53. AnnotationURLCitation(end_index=24074, start_index=23930, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L211%20,cells%20during%20exhaustion%20and%20in')
54. AnnotationURLCitation(end_index=24448, start_index=24304, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L211%20,cells%20during%20exhaustion%20and%20in')
55. AnnotationURLCitation(end_index=24856, start_index=24702, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L215%20adoptive%20cell,T%20cell%20responses%20in%20mouse')
56. AnnotationURLCitation(end_index=25193, start_index=25069, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=,cells%20during%20exhaustion%20and%20in')
57. AnnotationURLCitation(end_index=26139, start_index=25961, title='Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9998968/#:~:text=To%20identify%20SHP2i%20resistance%20mechanisms%2C,sensitization%20to%20SHP2i%20required%20its')
58. AnnotationURLCitation(end_index=26464, start_index=26286, title='Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9998968/#:~:text=To%20identify%20SHP2i%20resistance%20mechanisms%2C,sensitization%20to%20SHP2i%20required%20its')
59. AnnotationURLCitation(end_index=27724, start_index=27563, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=RASA2%20and%20RASA3%2C%20which%20are,T%20cell%20activation%20and%20migration')
60. AnnotationURLCitation(end_index=27852, start_index=27725, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=Repeats,these%20GAPs%2C%20how%20they%20are')
61. AnnotationURLCitation(end_index=28200, start_index=28073, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=Repeats,these%20GAPs%2C%20how%20they%20are')
62. AnnotationURLCitation(end_index=28559, start_index=28436, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=,T%20cell%20dysfunction%20in%20disease')
63. AnnotationURLCitation(end_index=28701, start_index=28560, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=match%20at%20L221%20,expression%20of%20Rasa3%20and%20its')
64. AnnotationURLCitation(end_index=29832, start_index=29645, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=Cutaneous%20melanoma%2C%20for%20which%20incidence,additional%20targetable%20alterations%20in%20melanoma')
65. AnnotationURLCitation(end_index=29961, start_index=29833, title='Recurrent inactivating RASA2 mutations in melanoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4954601/#:~:text=We%20compiled%20somatic%20mutation%20data,of')
66. AnnotationURLCitation(end_index=30489, start_index=30371, title='Mind the GAP: RASA2 and RASA3 GTPase Activating Proteins as gatekeepers of T cell activation and adhesion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10621891/#:~:text=B%29%20RAS,through%20a%20distinct')
67. AnnotationURLCitation(end_index=32745, start_index=32574, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=The%20RAS%20signaling%20pathway%2C%20a,overactive%2C%20fueling%20cancer%20growth%20and')
68. AnnotationURLCitation(end_index=32873, start_index=32746, title='A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12071082/#:~:text=,from%20general%20mechanisms%20and%20other')